Tilray Inc's latest earnings report revealed a significant shortfall, raising concerns among investors about the company's trajectory in the competitive pharmaceuticals market.
Recent earnings trend
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Tilray Inc
TLRY.TO
TLRY.TO
Tilray Inc
WealthAwesomeMarket cap
$727.16M
52W high
$32.30
52W low
$5.19
1W change
+5.18%
Beta
1.90
Analyst Price Targets
Based on analyst covering TLRY
Wall Street analysts forecast TLRY stock price to rise 37.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$8.09
+37.4% Upside
Current Price
C$5.89
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TLRY's historical volatility
30-Day Vol
39.4%
Annualized
90-Day Vol
54.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$4.93
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.55 | C$4.84 – C$6.36 |
| 60 trading days | C$5.23 | C$4.32 – C$6.34 |
| 90 trading days | C$4.93 | C$3.89 – C$6.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-05-31 | 2026-07-28 | 0.0500 | 0.2100 | -76.2% |
| 2026-02-28 | 2026-04-01 | 0.0200 | 0.0700 | -71.4% |
| 2025-11-30 | 2026-01-08 | -0.0200 | — | — |
| 2025-08-31 | 2025-10-09 | -0.0004 | -0.0300 | +98.7% |
| 2025-05-31 | 2025-07-28 | 0.0200 | 0.0100 | +100.0% |
| 2025-02-28 | 2025-04-08 | -0.8700 | -0.3300 | -163.6% |
Tilray Inc (TLRY.TO) reported its fiscal Q2 2026 earnings on July 28, 2026, and the results were disappointing. The company posted earnings per share (EPS) of $0.05, falling well short of the analyst consensus estimate of $0.21, marking a -76.19% surprise. This miss has raised eyebrows, especially considering the company's recent performance history and market conditions.
Investor takeaway: Investors should remain cautious as Tilray's earnings miss raises questions about its growth strategy and operational efficiency in a challenging market environment. With a significant divergence from expectations, the path forward may require strategic adjustments to regain investor confidence.
EPS Misses by 76.19% Amidst Competitive Pressures
Advertisement
Tilray's EPS of $0.05 stands in stark contrast to the estimate of $0.21, indicating significant challenges in meeting growth expectations as the company navigates the evolving pharmaceutical market.
Bull case
Despite the recent earnings miss, Tilray has shown resilience in past quarters, achieving beats in two of the last four reports. The company is focusing on expanding its product offerings and entering new markets, which could provide growth opportunities moving forward.
Bear case
The substantial earnings miss may indicate deeper operational issues. With a profit margin of -13.26% and a trailing twelve-month EPS of -1.54, investors may question the sustainability of Tilray's business model in a competitive landscape.
Earnings Overview
—
Analyst Insights
—
Wealth Awesome Price Forecast
—
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
